الفهرس 
PathohysiologyOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Background: The goal of antiviral treatment is to prevent complications of the disease, mainly cirrhosis and HCC. New therapy options, known as direct acting antiviral (DAA) regimens, offer the promise of increased success rates complimented by shorter treatment durations, improve side effect profiles, and simplified treatment monitoring.
Aim of the work: To compare between the effect of oral antiviral treatment especially (Quervo and Ribavirin) and (Sofosbuvir, Daclatasvir and Ribavirin) between elderly patients above 60 years and young people below this age as regard: Response to treatment, Development of complication.
patients and Methods: The study was conducted on 100 Egyptian patients they were divided into 2 groups each one received one of the two treatment regimens then each group divided into 2 subgroups, subgroup A include patients below 60 years and subgroup B include patients above 60 years. The selected patients were subjected to History taking, Complete physical examination, Pelviabdominal ultrasound, Laboratory investigations: complete blood count, bilirubin and liver enzymes before and after treatment, INR, creatinine, albumin, HBs Ag, HIV antibodies and Alpha feto proteins, HCV RNA.
Results: There is no significant difference between two treatment regimens. Both regimens show cure rate about 94%, 96% achieved SVR with (sofosbuvir daclatasvir and ribavirin regimen), (quervo and ribavirin regimen) respectively. Both regimens are effective in elderly patients above 60 years as young patients below this age in both regimens, response of treatment in both regimens in elderly patients above 60 years is 96%. Gender doesn’t affect treatment outcome. Anemia develop in 34% of patients receiving sofosbuvir, daclatasvir and ribavirin regimen, and in 58% of patients receiving quervo and ribavirin regimen. Females developed anemia more frequent than males in both regimens. Both regimens developed hepatobiliary complication, 12%, 18% developed hyperbilirubinemia with (sofosbuvir daclatasvir and ribavirin regimen), (quervo and ribavirin regimen) respectively.
Conclusions: treatment with (sofosbuvir daclatasvir and ribavirin regimen) or (quervo and ribavirin regimen) is highly effective with little differences between them; also age and gender have no role in achieving SVR. Complications such as anemia and hyperbilirubinemia occur in treatment with both regimens and more frequent with (quervo and ribavirin regimen).